The Caroline Foundation has been awarded €800,000 for breast cancer treatment research.
The award was funded by Science Foundation Ireland and Puma Biotechnology and will go towards advancing cancer research skills in DCU.
SFI provided €400,000 of the funding and the rest was provided by Puma Biotechnology, a biopharma company that specialises in the acquisition and development of novel therapeutics for the treatment of cancer.
The Caroline Foundation was established in memory of Greystones woman Caroline Dwyer-Hickey who died in 2013 aged 35 after a nine-year battle with cancer. Caroline was a patient of Professor John Crown from the time of her being diagnosed with breast cancer in June 2004, and was a public advocate for cancer research.
Published: Dec 18, 2020
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that its Investigational New Drug (IND) application for CAN106, a recombinant human monoclonal antibody targeting complement C5 of the complement system, has been approved by the Health Sciences Authority (HSA) in Singapore for the treatment of complement dysregulation diseases. The first indication is paroxysmal nocturnal hemoglobinuria (PNH), a fatal disease in which the complement system destroys red blood cells.
CAN106 is being developed for multiple diseases associated with complement dysregulation. The complement system is the part of the immune system that helps antibodies and phagocytic cells clear microbes and damaged cells. Dysregulation of the proteins that compose it leads to several rare diseases, including PNH. CANbridge holds the proprietary global righ
Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
Search jobs 11-Dec-2020 Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer
LOS ANGELES, Calif., December 11, 2020 / B3C newswire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial,” is being presented at a Spotlight Poster Discussion Session by Frankie Ann Holmes, M.D., FACP, Texas Oncology Houston – US Oncology Research, an
Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in